Bristol raises 2016 forecast after first-quarter earnings beat

April 28 (Reuters) - Bristol-Myers Squibb ratcheted

up its 2016 profit view after trouncing first-quarter sales and

earnings forecasts, driven by demand for its new Opdivo

immuno-oncology drug and its Eliquis blood clot preventer.

Read more